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Aminoglycoside—induced alterations of phosphoinositide metabolism.
There exists a strong interaction between aminoglycosides and phos-
phoinositides, and these membrane lipids are even considered as the
drug receptors. To shed some light on the role of such an interaction in
the drug nephrotoxicity, we have investigated the influence of ami-
noglycosides on phosphoinositide metabolism in kidney proximal tu-
bules where these compounds accumulate. Experiments were carried
out by measuring 32P labelling of phosphatidylinositol 4-phosphate
(PI-P) and of phosphatidylinositol 4,5-bisphosphate (PI-P2) after incu-
bation of homogenates of isolated proximal tubules with [y-32P] ATP.
The treatment of rabbits with neomycin, gentamicin and amikacin (50,
50 and 300 mg/kg/day, respectively for seven days) promoted a decrease
in 32P-PI-P2 and an increase in 32P-PI-P, when compared to the
respective values observed in tubules from untreated rabbits. Under
these conditions, the extent of modifications in lipid labelling was
similar with the three drugs tested. In in vitro experiments, the
exogenous addition of the above aminoglycosides to the incubation
medium containing tubule homogenates from untreated rabbits also
produced, in a dose dependent manner, a decrease in 32P-PI-P2 and an
increase in 32P-PI-P. In the in vitro experiments, however, amikacin and
gentamicin appeared to be less potent than neomycin. The results
indicated moreover that phosphoinositide metabolism was more sensi-
tive to the in vivo (vs. in vitro) action of the drugs. Phosphoinositides
are involved in Ca2 transport and/or mobilization processes, and
aminoglycosides are known to interfere with the Ca2 binding to
membranes. From our results, one may therefore envisage that amino-
glycoside—induced impairment of phosphoinositide metabolism can
result in a modification of Ca2 handling by the tubular cells and this
may be of relevance for the development of the drug toxicity.
In man and in experimental animals, the nephrotoxicity of
aminoglycosides can be ascribed to their accumulation in the
renal cortex [1, 2], and more precisely in proximal tubules [3—5].
Here, interactions occur between aminoglycosides and the
plasma membrane [3, 4, 6] and intracellular organelles such
as lysosomes [6—8] and mitochondria [9]. Aminoglycoside—
induced proximal tubule dysfunction, which may lead to
cell necrosis, has been recently reviewed [10, 11]. Acidic
phospholipids and most particularly phosphoinositides (phos-
phatidylinositol, P1; phosphatidylinositol 4-phosphate, PI-P;
phosphatidylinositol 4,5-bisphosphate, PI-P2) have been re-
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cently reported to play an important role in the binding of
aminoglycosides to brush border membrane of epithelial cells
[12]. In this respect, strong interactions between aminoglyco-
sides and phosphoinositides have been described [13—161.
Moreover, in the guinea pig renal cortex, the metabolism of
phosphoinositides has been shown to be altered by neomycin,
both in vivo and in vitro [16]. The biochemical events that are
responsible for the aminoglycoside—induced impairment of the
phosphoinositide interconversion have been analyzed, using a
biomembrane model, that is, the ghost membrane isolated from
rat erythrocyte [17]. In vivo experiments on aminoglycoside—
induced phospholipidosis in rat cortex, revealed also that, of all
the phospholipids, P1 exhibited the greatest percentage of
increase [18]. These observations, which led several authors
[12, 18] to propose that, in proximal tubules, phosphoinositides
might be considered as the anionic apical membrane receptors
for the cationic aminoglycosides, stimulated us to investigate
further the role of aminoglyco side! phosphoinositide interaction
in the nephrotoxicity of these drugs. For this purpose we have
studied the influence of aminoglycoside treatment on the phos-
phoinositide turnover. This was carried out by measuring the
32P incorporation into phosphoinositides after incubation with
[y-32P] ATP of homogenates of proximal tubules isolated from
drug—treated rabbits. The in vitro influence of aminoglycosides
on the phosphoinositide turnover was also studied by measur-
ing the 32P incorporation into the lipids after exogenous addition
of drugs to homogenates of proximal tubules isolated from
untreated rabbits. The 32P labelling of phosphoinositides was
considered to reflect the dynamic properties of these lipids. The
aminoglycosides studied were neomycin, gentamicin, and ami-
kacin.
Methods
Preparation of proximal tubule homogenates
Female rabbits, weighing 1.5 to 2 kg, were injected intramus-
cularly once daily, either with physiological saline or neomycin
(50 mg/kg, Sigma Chemical Co., St. Louis, Missouri, USA),
gentamicin (50 mg/kg, Schering, USA) or amikacin (300 mg/kg,
Bristol, Paris, France), for seven days. The antibiotics were
administered in a total volume of 2 ml using physiological saline
as diluent. Animals were killed by a blow on the head and
proximal tubules were isolated according to Hjelle, Morin and
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Trouet [19] as follows. After cannulation of the left renal artery,
the left kidney was perfused first with 20 ml of PBS (0.1 M, pH
7.4) and then with 10 ml of an iron oxide suspension fortified
with 2% polyvinylpyrrolidone at 37°C. The kidney was removed
and placed at 4°C for further dissection of cortex. Cortex was
minced prior to homogenization in cold PBS with six up and
down strokes with an hand—driven, modified Potter homoge-
nizer with a teardrop—shaped teflon pestle. Then the homoge-
nate was poured on to calibrated pore size sieves. The fraction
obtained between 110 and 54 micron was saved and contained a
mixture of proximal tubules and glomeruli. This suspension was
held over a magnet. Iron—loaded glomeruli were attracted on
the magnet while, as controlled in typical experiments by
histological procedures and as already published [19], a 98%
pure proximal tubule preparation remained in suspension. The
preparations obtained from treated rabbit kidneys could not be
distinguished, either in terms of yield or of purity, from those of
controls. Proximal tubules were collected in HEPES buffer (50
mM, pH 6.8), sonicated 2 x 5 seconds and centrifuged at 1000
g for 20 mm in order to remove undisrupted pieces. The
supernatant, considered as the proximal tubule homogenate,
contained 10 to 20 mg protein per ml, as measured by the
method of Lowry et al [20]. It was stored at —80°C and used
within five days. The homogenate was frozen and thawed four
times before 32P incorporation experiments.
Influence of aminoglycoside on the phosphoinositide
metabolism
In ex vivo experiments, tubule homogenates from aminogly-
coside—treated rabbits were compared with those from un-
treated animals for their capacity to incorporate, in the test
tube, 32P into phosphoinositides. Using [y-32P] ATP as the label
precursor, the 32P incorporation into phosphoinositides was
carried out according to Schibeci and Schacht [16] with slight
modifications. In brief, after preincubation for 10 minutes at
37°C of 0.3 mg protein of proximal tubule homogenate, the
incorporation reaction (performed in 50 mtvi HEPES buffer, pH
6.8) was initiated by adding 10 mrvi MgCI2 and 2 mtvi ATP
(containing 5 to 10 sCi [y-32P] ATP, 2000 to 3000 Ci/mmol,
Amersham, UK) in 0.5 ml final volume. The reaction was
stopped after 10 minutes of incubation at 37°C.
In in vitro experiments, tubule homogenates from untreated
rabbits were studied for their capacity to incorporate 32P into
the phosphoinositides, after the exogenous addition in the test
tube, of aminoglycosides (or solvent for controls). In these
experiments, the homogenates from untreated rabbits were
preincubated for 10 minutes at 37°C in the presence (or absence
for controls) of the desired aminoglycoside concentration. Then
the 32P incorporation reaction was carried out as described in
the preceding paragraph.
In another series of in vitro experiments, the above protocol
was used, but the aminoglycosides were exogenously added to
homogenates of proximal tubules prepared from drug—treated
animals.
Phospholipid analysis
The 32P incorporation reaction was stopped by adding 3.75
volumes of cold chloroform/methanol/concentrated HC1 (20/
40/liter, vol/vol/vol) directly to the incubation medium. The
Table 1. Blood creatinine levels and aminoglycoside contents in






Control (11) 79.09 3.25 —
Neomycin (7) 113.00 l.87a 2.9 0.2
Gentamicin (5) 136.33 1.36° 4.4 1.2
Amikacin (6) 158.20 0.97° 34.4 5.7
a p < 0.01 vs. control
resulting single phase was partitioned by addition of 1.25
volumes each of chloroform and distilled water and centrifuged
for 10 minutes at 1500 g. After removal of the upper phase, the
lower chloroformic phase was evaporated to dryness under N2,
dissolved in 0.1 ml chloroform and stored overnight at —30°C
before analysis. The phosphoinositides were separated by
one—dimensional thin layer chromatography on cellulose pre-
coated plates (Merck, Darmstadt, W. Germany) using n-
butanol/acetic acid/water (75/10/25, vol/vol/vol) as solvent, and
lipids were stained as already described [21]. After drying the
plates in air, the areas corresponding to phosphoinositides
(identified by comparison with co-chromatographed authentic
phosphoinositide samples) were scraped off and counted for
radioactivity in 4 ml of Unisolve (Koch—Light, Colnbrook,
UK). Preliminary experiments have shown that the lipid extrac-
tion and separation were not affected by the presence of
aminoglycosides.
Other experimental procedures
Blood levels of creatinine were measured according to the
Jaffe reaction [22].
In tubule homogenates isolated from treated rabbits, amino-
glycoside concentrations were determined microbiologically by
an agar diffusion assay using antibiotic medium 5, pH 8.0
(Difco, Detroit, Michigan, USA) and Bacillus Subtilis ATC
6633 as the test organism [23]. Standards for each aminoglyco-
side were prepared in the presence of tubule homogenates (0.5
mg protein/ml), obtained from control rabbits. Each assay was
performed in triplicate at two different dilutions.
2p measurements were performed in duplicate for each
animal. The 32P labelling of phosphoinositides was expressed as
32p pmol incorporated into P1-P2 (or PI-P) per mg protein per 10
minutes. To take into consideration the variations due to
animal, the 32P-PI-P2/32P-PI-P ratio was also calculated for each
animal. The values are given as the mean SEM of N animals.
Unless otherwise stated the unpaired Student's t-test was used
for statistical analysis.
Results
Blood creatinine was increased after all three aminoglycoside
treatments. The greatest increase was induced by amikacin
treatment (Table I).
Aminoglycoside accumulation within proximal tubules was
greater with amikacin than with gentamicin or neomycin (Table
1). Gentamicin or neomycin levels in proximal tubules were
within the usual range.
Electron microscope examination of proximal tubules iso-
lated from gentamicin— or neomycin—treated rabbits (not
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Fig. 1. Effect of aminoglycoside treatment on the 32P labelling of
phosphoinositides in proximal tubules. The tubules were isolated from
untreated rabbits (C, N = 14) or from rabbits which were injected with
neomycin (N, N = 8), gentamicin (0, N = 7) or amikacin (A, N = 6).
Values of 32P-PI-P2 and 32P-PI-P are expressed as 32P pmol incorporated
per mg prot per 10 mm. The statistical analysis was made with the
unpaired Student's t-test. Symbols are: < 0.05, < 0.02,
0.01, < 0.001.
shown) revealed the presence of a moderate amount of myeloid
bodies. No extensive necrosis was therefore induced by the
drug treatment.
32P-labelling of phosphoinositides in proximal tubule
homogenate
In preliminary experiments, using homogenates originating
either from untreated or from treated rabbits, data indicated
that, under the conditions used, the polyphosphoinositide la-
belling reached a plateau after a 10 minute incubation period
and that this labelling was not limited by 2 mrvi ATP (not
shown). In agreement with Schibeci and Schacht [16] whose
conditions were very close to the ones we used, we found that
about 90% of the label was incorporated into P1-P and P1-P2.
The remaining 10% was associated with P1 and PA (phosphati-
dylinositol and phosphatic acid, respectively).
Effects of aminoglycoside treatment (Fig. 1)
These effects were studied by measuring the radioactivity
incorporated into the phosphoinositides of proximal tubule
homogenates prepared from control animals or from aminogly-
coside—treated animals. Under the experimental conditions
defined above, when homogenates originating from control
animals were incubated with [y-32P] ATP, the amount of radio-
activity associated with P1-P2 and P1-P was 66 6 and 87 8
32p pmol/mg protein (N = 14), respectively and the mean ratio
between 32P-PI-P2 and 32P-PI-P was 0.81 0.14. When the
experiments were carried out with homogenates originating
from neomycin—, gentamicin— or amikacin—treated animals,
32P-PI-P2 and 32P-PI-P levels were 30 to 40% lower and 30 to
50% higher, respectively than the relevant values in controls.
As a result, the ratio 32P-PI-P2/32P-PI-P observed after amino-
glycoside treatment fell markedly to 0.3—0.4. These differences
were statistically significant. On the other hand, whichever the
parameter considered (32P-PI-P2, 32P-PI-P or the ratio between
Fig. 2. In vitro effect of neomycin on polyphosphoinositide—labelling of
proximal tubules. Tubules, isolated from untreated rabbits were prein-
cubated for 10 minutes with various neomycin concentrations, before
the initiation of 32P incorporation reaction. 32P-PI-P (0) and 32P-PI-P2
(Lx) values are expressed as the percentage of the values in the absence
of neomycin. The inset represents the variation of the ratio 32P-PI-
P2/32P-PI-P as a function of the neomycin concentration. Results are
representative of three separate experiments (one animal per
experiment).
these values), no significant difference could be detected be-
tween the three groups of treated animals. 32P-PI and 32P-PA
values in treated animals did not differ from the respective
values in controls (result not shown).
In vitro effects of amino glycosides
These experiments were carried out by adding, in the test
tube, the aminoglycoside to homogenate of proximal tubules
originating from untreated rabbits, 10 minutes prior to the 32P
incorporation reaction. The addition of neomycin, in the range
l0 to l0 M, decreased 32P-PI-P2 and concomitantly in-
creased 32P-PI-P in a dose—dependent manner (Fig. 2) without
modifying 32P-PI and 32P-PA (not shown). Hence, in this range
of concentration, the value of the ratio 32P-PI-P2/32P-PI-P de-
creased from 0.8 (for neomycin concentration lower than 5 x
lO_6 M) to 0.2—0.3 at 6 X iO M (Fig. 2). These variations
remained unaffected when the drug was added to homogenate
20 minutes prior to the labelling reaction. Such in vitro effects
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Table 2. In vitro effects of aminoglycosides on the
polyphosphoinositide labeling of proximal tubulesa
Addition
P1-P2 P1-P (32P-PI-P2/32P-PI-P)
x 10032P pmol/mg prot/lO mm
None (8) 66 5 89 10 80 10
Neomycin (8)
0.3 mM 43 3" 145 13" 28 3C
Gentamicin
0.3 mM (3) 76 4 93 16 95 15
3 mM (4) 35 1b 134 2O' 27 8"
Amikacin
3 mM (4) 50 14b 124 19b 42 10b
a The number of animals is indicated in brackets. The ratio (32P-PI-
P2/32P-PI-P) x 100 is the mean SEM of individual ratios. Statistical
analysis was made vs. controls (no addition).
b P < 0.05
"P < 0.01
ever, these aminoglycosides appeared to be less potent than
neomycin. When added at 3 x l0 M, neomycin significantly
modified 32P-PI-P2 and 32P-PI-P levels which were 66% and
164%, respectively of the control values (Fig. 2 and Table 2). By
contrast, the addition of 3 x l0— M gentamicin (Table 2) or
amikacin (not shown), had no effect on the 32P labelling of
phosphoinositides. Nevertheless, when added at higher concen-
trations, gentamicin and amikacin were observed to be capable
of decreasing the 32P incorporation into P1-P2 and of increasing
the 32P incorporation into P1-P. Our results (Table 2) showed
that 3 x i0 M gentamicin and amikacin significantly lowered
32P-PI-P2 (by 30 to 50%) and enhanced 32P-PI-P (by 40 to 50%),
hence decreasing the ratio between 32P-PI-P2 and 32P-PI-P from
the control value down to 0.3—0.4.
Whether they were obtained in cx vivo or in in vitro experi-
ments, the aminoglycoside—induced variations in 32P-PI-P2 and
32P-PI-P, could also be observed under different labelling con-
ditions. Using pH 7.4 instead of 6.8 diminished only slightly the
extent of variations (not shown). Moreover, varying the MgC12
concentration in the ranges 5 to 30 m (not shown) or varying
the length of the incorporation reaction in the ranges 5 to 20
minutes (Fig. 3), did not markedly affect the drug action.
In a third set of experiments, we investigated whether the
alteration of phosphoinositide metabolism induced in vivo by
the drug treatment, could influence the susceptibility of tubule
preparations to a further in vitro exposure to aminoglycosides.
For this purpose, we studied whether or not the exogenous
addition of aminoglycosides could still alter the 32P labelling of
phosphoinositides in proximal tubules isolated from amino-
glycoside treated animals. In these experiments, 32P-PI-P2 and
32PP1P levels were measured in homogenates originating from
neomycin— and gentamicin—treated rabbits which were incu-
bated in the absence (for control) and in the presence of
neomycin or gentamicin. As shown in Table 3, the addition of 3
X 1O M neomycin was no longer capable of decreasing
32P-PI-P2 but was still efficient on the P1-P labelling which
significantly increased by 40%. The decrease in the value of the
ratio 32P-PI-P2/32P-PI-P was not statistically significant due
probably to the slight increase in 32P-PI-P2. On the other hand,
the exogenous addition of 3 x l0- M gentamicin, which did not
affect the 32P-labelling of phosphoinositides in homogenates
Time, mm
Fig. 3. Influence of the length of the incorporation reaction upon the
aminoglycoside—induced variations of polyphosphomnositide labelling.
Proximal tubule homogenates were incubated for 5, 10 or 20 minutes at
37°C in 50 mt Hepes buffer, pH 6.8 with 2 mai ATP (containing the
labelled precursor) and 10 mi MgCI2. In A and B, tubule homogenates
were prepared from neomycin and gentamicin—treated rabbits, respec-
tively. In C, 0.3 mi neomycin was exogenously added to tubule
homogenates prepared from untreated rabbits. The modifications in
32P-PI-P2 (Lx) and in 32P-PI-P (0) are expressed as the percentage of
values obtained in a control experiment, that is, when tubule homoge-
nates from untreated rabbits were incubated for labelling in the absence
of aminoglycoside. Values are the mean of two experiments.
from untreated animals, was still inefficient in homogenates
from neomycin— and gentamicin—treated animals (results not
shown).
Discussion
The in vitro effects of aminoglycosides upon phosphoinosi-
tide metabolism have been documented in various systems. By
contrast few data are available concerning the influence of these
drugs in vivo. Following aminoglycoside treatment of animals,
examination of the kidney content in the phosphoinositides or
of the radioactivity associated with them after 32P injection gave
results which differ according to the authors and the experimen-
tal protocols [16, 18, 241. It is likely that the minute amount of
phosphoinositides in kidney—as in most tissues—the rapid post
mortem degradation and the rapid turnover of these lipids can
account for the differences reported. Using another experimen-
tal approach, we therefore examined the in vivo influence of
three aminoglycosides (neomycin, gentamicin, amikacin) on the
phosphoinositide turnover in kidney. This was carried out by
measuring the 32P incorporation into phosphoinositides follow-
ing the incubation of isolated proximal tubule homogenates
(originated from aminoglycoside—treated or untreated rabbits)
with [y-32P1 ATP for short time periods before extracting
phospholipids. The fact that under our experimental conditions
most of the label was associated with P1-P and P1-P2. indicated
that: i) only the monoester phosphate group(s) have incorpo-
rated the label and ii) the phosphodiesterasic cleavage of these
lipids did not function very actively. Since, on the other hand,
the aminoglycosides did not affect 32P-PI and 32P-PA, the
aminoglycoside—induced modifications of radioactivities asso-
ciated with P1-P and P1-P2 reflect the influence of the drugs on
the phosphoinositide interconversion mechanisms.
After treatment of animals with neomycin, gentamicin and
amikacin, 32P-PI-P2 and 32P-PI-P in tubules, were markedly and
significantly decreased and increased, respectively, when com-
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Table 3. Effects of exogenous addition of neomycin to homogenates from neomycin- and gentamicin—treated animals
32p_pJ_p2a 32p_pJ_pC 32p_p_p2/32p_pJ_pb
Neomycin—treated 29 4 86 6 0.34 0.03N= 4
+ 0.3 mM Neomycin 32 6(111 15%) 120 11(139 7%)C.d 0.27 0.06e
Gentamicin—treated 32 3 82 19 0.37 0.10
N= 3
+ 0.3 mM Neomycin 31 10(111 24%) 112 19(140 l0%) 0.27 0.04
C Values expressed as 32P pmol incorporated per mg proteinb Mean SEM of individual ratios
Percentage of the value obtained in the absence of added neomycin are shown in parentheses
d P < 0.01
NS
order to determine whether the effects observed in proximal
tubule homogenates prepared from treated rabbits could be due
to the amount of aminoglycoside present in the homogenates,
experiments were undertaken to examine the intrinsic in vitro
influence of these drugs on the 32P labelling of P1-P and P1-P2.
For this purpose the aminoglycosides were added exogenously
to homogenates of proximal tubules isolated from untreated
rabbits, prior to the 32P-incorporation reaction. Our results
clearly indicate that under such conditions, the three drugs
studied (when added in the test tube at the appropriate concen-
tration, that is,  i0- M for neomycin and in the millimolar
range for gentamicin and amikacin) could both decrease 32P-PI-
P2 and increase 32P-PI-P levels. Under experimental conditions
close to the ones used here, similar in vitro results have been
already reported with various aminoglycosides in different
systems [16, 17, 25, 261. In the view of the antibiotic content in
tubules of treated rabbits (Table 1) and given the protein
amount used for the labelling (0.3 mg in 0.5 ml total volume),
the drug concentrations in homogenates originating from these
animals could be calculated as being 3, 6 and 35 p.M for
neomycin, gentamicin and amikacin, respectively. Such drug
concentrations, which moreover did not correlate with 32P-PI-
P2, 32P-PI-P or with the ratio between these values, could not
therefore account for the variations that we observed in the 32P
labelling of phosphoinositides after the antibiotic treatment.
The alterations in phosphoinositide metabolism observed in
our ex vivo experiments can result: i) from treatment—induced
alterations of activities of kinases and/or phosphatases (the
enzymes responsible for the phosphoinositide interconversion,
hence for the phosphoinositide labelling); and/or ii) from treat-
ment—induced changes in the amount and/or the accessible pool
size of P1, P1-P and P1-P2 as has been inconstantly reported in
the literature [16, 18, 24]. It is worthy to note that the latter
possibility implicates that the former one did occur, that is, that
enzymic pathways involved in phosphoinositide metabolism
have been altered during the drug treatment. In our studies, ex
vivo experiments demonstrate that the aminoglycoside admin-
istration modified the capacity of polyphosphoinositides to
incorporate 32P. Thus, although the respective distribution in
the various phosphoinositides was not measured after the
treatment, our data indicate that aminoglycoside treatment
impaired the kidney proximal tubules in such a way as to alter
the metabolism of phosphoinositides.
This hypothesis was strengthened by our results on the
exogenous addition of aminoglycosides to tubule homogenates
prepared from neomycin— or gentamicin—treated rabbits. In
tubule homogenate from untreated rabbits, after incubation in
the presence of 0.3 m'vi neomycin, 32P-PI-P2 and 32P-PI-P levels
were 66 and 164%, respectively, of the levels in the absence of
drug (Table 2). By contrast, after addition of 0.3 mM neomycin
to tubule homogenate from treated animals, 32P-PI-P2 and
32PP1..P levels were 111 (NS) and 140%, respectively, of the
levels in the absence of drug (Table 3). Such a difference on the
P1-P2 labelling indicates that tubules isolated from the drug—
treated rabbits were in some way desensitized and suggests
furthermore that the neomycin capacity of lowering in vitro the
32p incorporation into P1-P2 was abolished because the mecha-
nisms involved in such an effect have already been impaired
during the in vivo treatment.
The observation that with both experimental procedures, that
is in vivo treatment or in vitro addition of drugs, 32P-PI-P2
decreased and 32P-PI-P increased, could suggest that in both
protocols, the effects of drugs on the parameters we measured
operated via similar mechanisms. However, one cannot ex-
clude the possibilities that: i) the phosphoinositide pool sizes
have been modified by the drug treatment (see above); and ii)
the enzyme—activities responsible for the lipid labelling could
have been damaged differentially (in tubules issued from control
rabbits compared with tubules issued from treated rabbits)
during the preparation of tubule homogenates. These reserva-
tions prevent us, therefore, to rely on the drug—induced changes
in lipid labelling for determining the mechanism(s), whereby
aminoglycosides impair the phosphoinositide interconversion in
each of the protocols we used.
To account for the apparent greater sensitivity of the phos-
phoinositide labelling to in vivo (vs. in vitro) actions of drugs,
one may envisage that a much longer period of contact of drugs
with homogenates (a period so long that it cannot be achieved
under our present labelling conditions since most of
homogenate components including the phosphoinositides
would be degraded) would increase the sensitivity of our in
vitro procedure. Likewise the possibility that specific poo1s of
phosphoinositides and/or of the components involved in their
metabolism were affected by in vivo exposure to high drug
doses for seven days, cannot be ruled out and may further
explain the apparent discrepancy between ex vivo and in vitro
studies.
The impairment of phosphoinositide turnover may have some
functional consequences in cell reactivity. Phosphoinositide
metabolism is undoubtedly related to the cell activation pro-
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cesses which involve Ca2 as a second messenger [27]. Recent
evidence indicates moreover that P1-P2 (and maybe also PI-P)
are involved in the earliest events that follow the activation of
Ca2 mobilizing receptors [28]. In addition P1-P2 could be
involved per se in the transmembrane Ca2 transport [29]. In
other words, the polyphosphoinositides appear to be as key
components of cell membrane for controlling the variations in
intracellular Ca2 concentrations whereby cell physiological
responses are evoked. Therefore from this study, which to our
knowledge is the first to demonstrate that aminoglycoside
treatment impairs the phosphoinositide metabolism in kidney
proximal tubules, it is not unreasonable to envisage that such a
membrane alteration results in modifications of Ca2 transport
processes and/or of cell Ca2 homeostasis, thereby impairing
cell responses to natural stimuli. For example, the alteration of
calcium homeostasis recently observed after aminoglycoside
exposure [30] could be a consequence of impaired phosphoin-
ositide turnover. We therefore suggest that the aminoglyco-
side—induced modification of phosphoinositide interconversion
may be of relevance in the development of the drug toxicity.
Reprint requests to Pierre Marche, Department of Pharmacology,
INSERM U7, Hopital Necker, 161 rue de Sèvres, 75015 Paris, France.
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